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Comparison of Proliferating Cell Nuclear
Antigen to Tritiated Thymidine As a Marker of
Proliferating Hepatocytes in Rats
by Julie Foley,1 Thai Ton,1 Robert Maronpot,1
Byron Butterworth,2 and Thomas L. Goldsworthy2
Proliferating cell nuclear antigen (PCNA), an endogenous nuclear protein, has recently been
used to identify replicating cells. PCNA was compared to tritiated thymidine ([3Hl-TdR), a reli-
able and accurate exogenous labeling agent, to ascertain if PCNA gives comparable results for
quantitative cell proliferation. Male F344 rats were treated with a single dose of 500 mg/kg
4-acetylaminofluorene (4-AAF), a known liver mitogen. Rats (n = 5) were euthanized and
necropsied at 6, 12, 18, 24, 36, 48, 96, or 192 hr after treatment. Two hours before necropsy, rats
were pulse-dosed with [3H]-TdR (2 mCi/kg body weight). Livers were sectioned, autoradiogra-
phy performed, and labeling indexes (LI), a measurement of the percentage of S-phase hepato-
cytes, determined. One and a halfyears after the completion ofthis study, the archival paraffin
blocks ofthe liver tissue were sectioned and stained for PCNAby an immunohistochemical pro-
cedure. Immunocytochemical staining patterns ofproliferating cell nuclear antigen expression
permitted the recognition of G,, S, G2, M, and quiescent cells. PCNA LI, generated by scoring
only cells exhibiting S-phase staining patterns, was compared to the pulse [3H]-TdR LI for each
animal. Similar periportal staining patterns of S-phase nuclei were detected by both markers.
The [3H]-TdR LI and the PCNA LI exhibited a peak at 24 hr of approximately the same magni-
tude. However, while the [3H]-TdR LI had returned to near baseline at the 48-hr time point, the
PCNA LI remained elevated until the 96-hr time point. This sustained elevation of the PCNA
index cannot be explained at this time. Examination of all other time points revealed similar S-
phase LI by either method. PCNA immunostaining allowed for the estimation of the growth
fraction. A time-dependent alteration in the hepatic growth fraction curve was a consequence
of4-AAF treatment.
Introduction
Proliferating cell nuclear antigen (PCNA), an
endogenous nuclear protein, has recently been used to
identify replicating cells in human and rodent tissues
(1-9). The PCNA amino acid sequence in the rat and
human differs by four residues, indicating a highly con-
served molecule (10). This 36-kD protein functions as
an accessory protein to DNA polymerase (pol) 6 (11,12).
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DNA pol 6, in conjunction with PCNA, is also respon-
sible for leading strand DNA synthesis in replicating
cells, whereas PCNA involved in DNA repair mecha-
nisms is independent ofDNA pol 6 (13). Studies ofcells
in culture have identified PCNA in G1, S, G2, and M
phases of the cell cycle with peak expression of the
protein during S phase (14-16). The advent ofcommer-
cially available antibodies of PCNA has allowed the
immunohistochemical detection and evaluation of this
endogenous cell-cycle-related protein as a marker of
replicating cells, which is ofparticular importance with
the recent interest in the role of cell proliferation in
chemical carcinogenesis (17,18).
Limited data exist that use PCNA for assessment of
chemically induced cell proliferation in rodent tissues.
The use of PCNA immunohistochemistry in rodent
studies depends on its sensitivity, reproducibility, and
comparability to other markers of cell proliferation. In
this report, we describe a) PCNA staining procedures
on archival hepatic tissue sections; b) the detection ofFOLEYETAL.
cell-cycle-specific phases after PCNA immunostaining;
and c) a comparison of PCNA to tritiated thymidine
([3H]-TdR) as a marker of chemically induced cell pro-
liferation.
Materials and Methods
Experimental Design
Male F344 rats, 12 weeks ofage, were treated with a
single dose of 500 mg/kg 4-acetylaminofluorene (4-
AAF), a known liver mitogen. Five rats each were
euthanized and necropsied at 6, 12, 18, 24, 36, 48, 96, or
192 hr after treatment. Two hours before necropsy,
rats were pulse-dosed IP with [3H]-TdR (2 mCi/kg
body weight). Livers were fixed in 10% neutral-
buffered formalin (NBF) for 2-3 weeks, embedded in
paraffin, sectioned, and autoradiography was per-
formed as described by Eldridge et al. (19). One and a
half years after the completion of the [3H]-TdR study,
archival paraffin blocks of the liver tissue were sec-
tioned and stained for PCNA by a immunohistochemical
procedure as described by Greenwell et al (20).
Modifications to this staining procedure, described here
in detail, were used to eliminate background staining.
PCNA Staining Procedure
This procedure applied to tissues fixed in 10% NBF
for extended periods of time (greater than 72 hr).
Liver tissues were sectioned at 6 gm and mounted on
tissue adhesive poly-l-lysine coated slides. Sections
were air dried, deparaffinized in xylene, and hydrated
through a graded series of ethyl alcohols to 1X
Automation Buffer, pH 7.5 (Biomeda Corporation, Fos-
ter City, CA). A highly sensitive biotin-streptavidin
method of immunohistochemical localization was per-
formed as follows (see Table 1 formaterials):
1. Quench endogenous peroxidase by placing slides in 3% H202
for5min.
2. Rinse and wash slides in distilled waterfor 5 min.
3. Place slides in plastic Coplin jar filled with antigen retrieval
solution. Microwave on high power (700 watts) for 2 mirr.
Check solution levels after 1 min and repeat high power
microwave for 2 min. If levels are decreased, add distilled
water.
4. Allow slides to cool for 15 min at room temperature in the
Coplinjars.
5. Discard retrieval solution and rinse two times in distilled
water.
6. Rinse in 1X automation buffer for 5 min.
7. Apply monoclonal antibody anti-PCNA (19A2). Incubate 30
min at room temperature.
8. Rinse in two changes of1X automationbuffer for 5 min each
9. Apply the link antibody. Incubate for 30 min at room temper-
ature.
10. Rinse in two changes of1X automation bufferfor 5 min each.
11. Apply the label antibody. Incubate for 30 min at room tem-
perature.
12. Rinse in two changes of 1X automation buffer for 5 min
each.
Table 1. Materials used for immunohistochemical localization
Material (supplier) Quantity
Reagents
1X Automation buffer, pH 7.5
(Biomeda Corporation, Foster City CA)
lOX Automation buffer 100.0 mL
Distilled Water 900.0 mL
Antigen Retrieval Solution
(Biogenex Laboratories, San Ramon, CA)
Deionized water 30.0 mL
Antigen Retrieval Solution 10.0 mL
(This is sufficient to fill 1 plastic Coplinjar)
3% Hydrogen peroxide (make fresh)
30% Hydrogen peroxide 1.0 mL
Distilled Water 9.0 mL
Substrate-Chromogen Solution
(may be prepared and stored at4°C)
30% Hydrogen peroxide 60.0jL
Distilled Water 100.0 mL
Add 1 diaminobenzidine (DAB) tablet Sigma
Corporation, St. Louis, MO) to 20 mL of
substrate reagent 25 min. beforeusing.
Antibody dilutions
Primary Antibody Diluent (Prepare fresh)
Nonfat powdered dry milk 0.5 g
Distilled Water 49.5 mL
Mix well. When ready to use, dilute with
equal parts of 1% bovine serum albumin (BSA)
in 1X automation buffer.
Primary antibody: monoclonal antibody mouse
anti-PCNA (19A2) (Coulter Immunology,
Hialeah FL) (prepare fresh); dilution 1:400
Monoclonal antibody mouse anti-PCNA 10.0 ,uL
Primary antibody diluent 3.9 mL
Link and label antibody (StrAviGen TM
Super Sensitive Prediluted Immunostaining
Kit, Biogenex Laboratories, San Ramon, CA)
Link Prediluted
(biotinylated anti-immunoglobulins, specific for mouse)
Label Prediluted
(streptavidin conjugated to horseradish peroxidase)
These kits may be purchased concentrated or prediluted.
Ifusing the concentrated kits, the link and label antibody
are diluted with 1% BSA in 1X automation buffer at a 1:10
dilution.
13. Rinse slides briefly with distilled water and remove excess
liquid fromthe surface ofthe slide.
14. Apply diaminobenzidine (DAB) solution to the tissue sections.
Incubate 6 min at room temperature in the dark. (Covercham-
berand turn outthe lights.)
15. Discard excess DAB and rinse slides in runningtap water for
3-5 min.
16. Counterstain in Harris hematoxylin (Harelco, Gibbstown,
NJ) for 1 min.
17. Rinse in tap wateruntil wateris clear.
18. Place slides in 1X automation buffer until sections are blue (3
min).
19. Rinse briefly in tap water.
20. Dehydrate the tissue sections through 95% and 100% ethanol
to xylene. Apply Permount (Fisher Scientific Co.,
Pittsburgh, PA) and coverslip.
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Cell Proliferation Counts Table 2. Criteria for phases ofcell cycle.
The [3H]-TdR labeling index (LI) for autoradi-
ographed, stained slides was calculated by dividing
labeled cells by the total number of cells counted (at
least 1000 hepatocytes) from the left lobe of the liver.
Nuclei containing at least 10 silver grains were scored
as labeled. Binucleated hepatocytes were scored as a
single hepatocyte.
For PCNA, the LI and growth fraction were gener-
ated for each animal using a serial cut ofthe same liver
section used for determining the [3:H]-TdR LI.
Immunocytochemical staining patterns of PCNA per-
mitted the recognition of GI, S, G2, M, and quiescent
(Gj) cells, as described in Table 2. PCNA LI was calcu-
lated by scoring hepatocytes exhibiting an S-phase
staining pattern. That is, the number of hepatocytes
displaying labeled dark brown to black nuclei in the
absence of cytoplasmic staining was divided by the
total number of hepatocytes counted (at least 1000
hepatocytes). Binucleated hepatocytes were scored as
a single hepatocyte. The growth fraction (21), an esti-
mation of hepatocytes active in the cell cycle, was
quantitated by dividing the total number of PCNA
stained hepatocytes (GI + S + G2+ M) by the total
number of hepatocytes counted (at least 1000 hepato-
cytes).
Cell cycle
criteria
Gil
Positive cell
criteria
No nuclear or
cytoplasmic
staining.
GI Patchy to uniform,
light brown nuclear
staining; no cytoplasmic
staining.
S Uniform, brown-dark
brown to black nuclear
staining; no cytoplasmic
staining.
G2 Diffuse, speckled
nuclear and cytoplasmic
staining.
M Diffuse, cytoplasmic
staining.
Results
The modified immunostaining procedure yielded con-
sistent staining patterns, limited background chro-
mogen staining, and allowed the reliable identification of
G,, S, G2, M, and Go hepatocytes. Initial attempts using a
previously described procedure (20) produced inconsis-
tent staining, increased background, and complications
in discriminating cell cycle phases. By reducing the
microwave time (i.e., heat exposure), consistent staining
was obtained with minimal background. Tissues fixed in
formalin for several months required longer microwave
incubation to permit optimal expression of the PCNA
antigen (data not shown). Since the tissue in this experi-
ment was fixed for a shorter time period (approximately
2 to 3 weeks), decreased microwave irradiation was
apparently required to permit select PCNA antigen
expression without background staining.
PCNA antigen-antibody complexes expressed vari-
ous staining patterns. The staining results were cate-
gorized based on cellular distribution and intensity of
the reaction product as shown in Table 2 and as previ-
ously described by Foley et al. (8). Go or quiescent
hepatocytes expressed no detectable staining. GI hepa-
tocytes were characterized by a patchy to uniform,
light-brown nuclear staining. Cells in S phase dis-
played uniform intense brown to black nuclear stain-
ing. Diffuse speckled-brown nuclear and cytoplasmic
staining characterized hepatocytes in the G2 phase.
Mitotic hepatocytes had diffuse and speckled-brown
cytoplasmic staining.
The growth fraction revealed that the majority of
hepatocytes were G, hepatocytes at 6, 12, and 18 hr
after 4-AAF treatment (Fig 1). For the next 32 hr,
78% of the cells were active in the cell cycle, dropping
to 45% at the 96 hr interval. The proportion ofactively
cycling cells returned to 3% at 192 hr. The individual
cell cycle phases ofthe growth fraction, as detected by
PCNA expression after 4-AAF exposure, are also
shown in Figure 1. The proportion of GI hepatocytes
was elevated after 24 hr (40%) and remained at peak
levels through the 96 hr (43%) interval before declining
to 3% at 192 hr. S-phase hepatocytes increased after 24
hr (23%) and remained elevated at 36 and 48 hr (17%
and 28%, respectively). At 96 and 192 hr, the propor-
tion of S-phase cells had declined to less than 2%. The
percentage of actively cycling cells that were G2- and
M-phase hepatocytes was greatest at 36 hr (21% and
4% respectively). At all other time points, less than 1%
of the G2- and M-phase cells accounted for the total
percentage of actively cycling hepatocytes. It is evi-
dent that 4-AAF treatment greatly altered the hepato-
cyte growth fraction (Fig. 1 and 2).
Because S-phase hepatocytes were recognized by
intense PCNA expression localized in the nucleus, an
attempt was made to quantitate these hepatocytes and
generate a LI to compare to the previously quantitat-
ed [3H]-TdR LI. Figure 3 demonstrates that [3H]-TdR
LI and the PCNA LI both exhibited a peak at 24 hr of
Example
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FIGURE 1. The percentage of hepatocytes in various phases of the cell cycle as detected by proliferating cell nuclear antigen after 4-acety-
laminofluorene (4-AAF) exposure. The growth fraction displayed atime-dependent alteration as a consequence of4-AAF treatment.
the same approximate magnitude. However, while the
[3H]-TdR LI had returned to near baseline at the 48 hr
time point, the PCNA LI remained elevated until the
96-hr time point. Examination of all other time points
revealed similar S-phase LI by either methods.
Discussion
An exciting aspect of visualizing replicating cells
with PCNA is the potential to assess the degree of
chemically-induced cell proliferation in archival mate-
rial in previously conducted experimental and animal
cancer bioassays. Results from these studies indicate
a proportional relationship under most conditions
between the [3H]-TdR LI and the PCNA LI in the
liver ofrats treated with 4-AAF. The monoclonal anti-
body to PCNA (19A2) has also allowed for the estima-
tion of the growth fraction in liver tissue. We
observed a time-dependent alteration in the hepatic
growth fraction curve as a consequence of 4-AAF
treatment. Information gained from the ability to esti-
mate the growth fraction will help with the under-
standing ofcell-cycle kinetics in normal and neoplastic
tissue.
Many investigators have attempted to ascertain the
validity of PCNA as an indicator of cell proliferation
by comparing PCNA to other markers such as [3H]-
TdR, BrdU, and Ki67 (3-5,7,9,22). Most ofthe correla-
tions have yielded good results with few exceptions
(7,23,24). Further investigation is warranted to under-
stand if the discrepancies noted in the exceptions are
related to PCNA gene regulation, PCNA expression in
different cell types, and/or differences in the antigenic-
ity of anti-PCNA antibodies (25). Variables in experi-
mental conditions including the use of different tissue
fixatives (formalin versus methanol) may result in a
lack of correlation between proliferation markers
(4,7,25-28). Discrepancies between PCNA and other
proliferative cell labeling methods may also result
from measuring different indicators of cell division.
Proliferative cell labeling markers such as [3H]-TdR
and BrdU measure the respective label incorporated
into the DNA of cells undergoing DNA synthesis.
PCNA as a proliferative cell marker measures the
expression of an antigen with a 20 hr half-life that is
maximally expressed in S-phase cells.
PCNA, used as an indicator of cell proliferation, has
advantages and disadvantages. There is no administra-
tion of a labeling compound; therefore, there is no ani-
mal surgery, anesthesia, or animal handling. Rapid
results are obtained through PCNA immunostaining of
retrospective or freshly fixed tissues imparting specif-
ic cell cycle stage information. Assimilated information
of specific cell-cycle stages allows for growth fraction
estimation, yielding more information on a chemical's
proliferative effects. PCNA detection can be a disad-
vantage when quantitating cell replication in a slow
turnover tissue. Continuous label administration via
osmotic minipumps are required to assess this prolifer-
ative data. PCNA LI are more comparable to pulse-
dosed [3H]-TdR and BrdU quantitated LI than LI
generated by continuous label administration. It is
important to remember that PCNA is present in GI, S,
G2 and M-phase cells. Since all cell-cycle phases are
recognizable by PCNA immunostaining, only those
cells that meet the positive PCNA scoring criteria as
an S-phase cell need to be compared to [3H]-TdR
and/or BrdU-S-phase measurements.
In the present study using a monoclonal antibody
(19A2) to PCNA, we retrospectively compared the use
of PCNA to [3H]-TdR as a marker for detecting S-
phase cells. Paraffin blocks of liver from a previously
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FIGURE 2. Immunohistochemical detection ofPCNA using a monoclonal anti-PCNA antibody (19A2). Hepatocytes active in the cell cycle were
observed by PCNA immunostaining: (A) 6 hr, (B) 12 hr, (C) 18 hr, (D) 24 hr, (E) 36 hr, (F) 48 hr, (G) 96 hr, and (H) 192 hr, after 4-acety-
laminofluorene treatment. Arrows with the specific cell-cycle phase are adjacent to the hepatocyte displaying the positive cell criteria.
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FIGURE 3. Detection of S-phase hepatocytes: proliferating cell
nuclear antigen (PCNA) versus tritiated thymidine ([3H] TdR).
The PCNA labeling index is comparable to the [3H]-TdR except at
48 hr after 4-acetylaminofluorene administration.
completed cell proliferation study using [3H]-TdR as
the labeling agent were used. Similar periportal stain-
ing after 4-AAF administration was observed in the
PCNA and [3H]-TdR stained slides, suggesting that
both labels were identifying the same population of
proliferating hepatocytes. The PCNA LI was similar
to the previously generated 2 hr [3H]-TdR pulse dose
LI at all time points except 48 hr, at which time there
was a significant increase in the PCNA LI over the
[3H]-TdR LI. The disparate results at 48 hr may
reflect a massive synchronous entry ofa cohort ofcells
into S phase during the time interval after [3H]-TdR
injection but before tissue sampling (7); potential
induction of growth factors by 4-AAF resulting in
detectable PCNA expression (25); or PCNA expres-
sion associated with DNA repair processes (13). The
latter possibility is unlikely since 4-AAF is not geno-
toxic (29,30) Further studies are under way to deter-
mine the causative differences between the labeling
indexes at this time point.
The monoclonal antibody to PCNA (19A2) recognized
an antigen differently expressed in the G1, S, G2, and M
phases of the cell cycle. Consequently, PCNA analysis
was used as an estimator ofthe cell-cycle growth frac-
tion, yielding new information on the behavior of non-
cycling hepatocyte populations and their transition to
an activelyproliferating state. Identification ofa chemi-
cal's effect on individual cell cycle populations and the
total proliferating pool of cells may yield new and
potentially valuable information in understanding
chemically induced cell proliferation. By adding the
specific cell-cycle phases together, it was of interest
that approximately 60-80% of hepatocytes were in the
active phase ofthe cell cycle following a single adminis-
tration of a mitogen. Such analysis may lead to an
improved determination ofspecific cell populations that
should be affectedby chemical exposure.
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